EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Real-world evaluation of the FluoroType MTBDR 2.0 assay for detection of rifampicin and isoniazid resistance-conferring mutations in Mycobacterium tuberculosis complex clinical isolates

Fabiane Maria de Almeida Ferreira, Angela Pires Brandão, Thiago Brobio Massanti, Antonio Carlos da Silva Rego, Lucilaine Ferrazoli, Erica Chimara, Rosângela Siqueira de Oliveira, Juliana Maira Watanabe Pinhata iD

Microbiology Spectrum · 03.11.2026 · 14 (11)

DOI: 10.1128/spectrum.01880-26 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Microbiology Spectrum, erschienen am 03.11.2026. Verfasst von Fabiane Maria de Almeida Ferreira und 7 weiteren Autor:innen. Beteiligte Einrichtung: Núcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Rifampin, Isoniazid, Antitubercular Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Health Fund for Mass Immunization and Disease Control.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-resistant tuberculosis (TB) remains a major global health challenge, particularly in high-burden settings, where rapid detection of resistance to rifampicin (RIF) and isoniazid (INH) is essential for timely treatment. The FluoroType MTBDR assay is an automated real-time PCR platform for simultaneous detection of Mycobacterium tuberculosis complex (MTBC) and resistance to RIF and INH. This study aimed to evaluate the performance of FluoroType using clinical MTBC isolates under routine laboratory conditions in a reference setting. The assay was prospectively assessed in comparison with the GenoType MTBDR plus line probe assay (LPA) using 1,841 clinical isolates, with discordant results resolved by Sanger sequencing. For MTBC detection, FluoroType achieved 100% sensitivity (1,807/1,807), 88.2% specificity (30/34), and 99.8% overall accuracy. FluoroType demonstrated 99.9% (1,683/1,685) sensitivity in detecting wild-type isolates. For resistance detection, FluoroType showed 95.5% sensitivity for RIF (42/44) and 94.4% for INH (34/36). Among multidrug-resistant isolates, sensitivity was 85.4% (35/41). Discordances were mainly associated with heteroresistance, and uncommon or synonymous mutations. Importantly, limitations in identifying specific mutations highlight the need for cautious interpretation and, when necessary, confirmatory sequencing. Overall, these findings support FluoroType as a rapid, high-throughput, and reliable tool for MTBC detection and drug resistance profiling in reference laboratories. IMPORTANCE This study is the first to prospectively evaluate the FluoroType MTBDR assay performance using a large collection of clinical isolates under routine conditions in a high-burden tuberculosis (TB) reference laboratory. It assesses detection of Mycobacterium tuberculosis complex and resistance to rifampicin and isoniazid. Drug-resistant TB remains a major global health challenge, requiring rapid and reliable diagnostic tools. FluoroType demonstrated high accuracy and operational advantages over the line probe assay (LPA), including a streamlined workflow and reduced turnaround time for high-throughput settings. Importantly, this study highlights limitations shared by molecular assays, particularly in detecting and interpreting heteroresistance, uncommon mutations, and synonymous rpoB variants, which may lead to discrepant resistance classification across platforms. These findings underscore the need for cautious interpretation of molecular results and sequencing to resolve clinically relevant discrepancies. Overall, FluoroType is a valuable addition to TB diagnostic algorithms, but results should be interpreted in the context of assay-specific limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisRifampinIsoniazidAntitubercular AgentsTuberculosis, Multidrug-ResistantDrug Resistance, Multiple, BacterialHumansMutationSensitivity and SpecificityMicrobial Sensitivity TestsBacterial ProteinsReal-Time Polymerase Chain ReactionProspective Studies

Stichwörter der Autor:innen

FluoroType MTBDRMycobacterium tuberculosisdrug resistanceline probe assaymultidrug-resistant tuberculosis

Substanzen

RifampinIsoniazidAntitubercular AgentsBacterial Proteins

Autor:innen und Institutionen

  • Núcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, São Paulo, Brazil.
  • Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Mobius Lifescience, Pinhais, Paraná, Brazil.

ORCID-Profile: Juliana Maira Watanabe Pinhata

Förderung

  • Special Health Fund for Mass Immunization and Disease Control

Zitieren

APA

Ferreira, F. M. A., Brandão, A. P., Massanti, T. B., Rego, A. C. S., Ferrazoli, L., Chimara, E., de Oliveira, R. S., & Pinhata, J. M. W. (2026). Real-world evaluation of the FluoroType MTBDR 2.0 assay for detection of rifampicin and isoniazid resistance-conferring mutations in Mycobacterium tuberculosis complex clinical isolates. Microbiology Spectrum, 14(11). https://doi.org/10.1128/spectrum.01880-26

Vancouver

Ferreira FMA, Brandão AP, Massanti TB, Rego ACS, Ferrazoli L, Chimara E, et al. Real-world evaluation of the FluoroType MTBDR 2.0 assay for detection of rifampicin and isoniazid resistance-conferring mutations in Mycobacterium tuberculosis complex clinical isolates. Microbiology Spectrum. 2026;14(11). doi:10.1128/spectrum.01880-26

BibTeX
@article{Ferreira2026,
  author = {Ferreira, Fabiane Maria de Almeida and Brandão, Angela Pires and Massanti, Thiago Brobio and Rego, Antonio Carlos da Silva and Ferrazoli, Lucilaine and Chimara, Erica and de Oliveira, Rosângela Siqueira and Pinhata, Juliana Maira Watanabe},
  title = {Real-world evaluation of the FluoroType MTBDR 2.0 assay for detection of rifampicin and isoniazid resistance-conferring mutations in Mycobacterium tuberculosis complex clinical isolates},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1128/spectrum.01880-26}
}
Kostenlos starten →